National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection

Ryan J. Ellis, Jessie W. Ho, Cary Jo R. Schlick, Ryan P. Merkow, David J. Bentrem, Karl Y. Bilimoria, Anthony D. Yang*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Introduction: Chemotherapy is increasingly administered prior to resection in patients with early-stage pancreatic adenocarcinoma, but the national prevalence of this practice is poorly understood. Our objectives were to (1) describe the utilization of upfront chemotherapy management of stage I pancreatic cancer; (2) define factors associated with the use of upfront chemotherapy and subsequent resection; and (3) assess hospital-level variability in upfront chemotherapy and subsequent resection. Methods: The National Cancer Database was used to identify patients treated for clinical stage I pancreatic adenocarcinoma. Outcomes were receipt of upfront chemotherapy and surgical resection after upfront chemotherapy. Associations between patient/hospital factors and both initial management and subsequent resection were assessed by multivariable logistic regression. Results: A total of 17,495 patients were included, with 26.6% receiving upfront chemotherapy. Upfront chemotherapy was more likely in patients who were ≥ 80 years of age (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.39–1.93), had T2 tumors (OR 2.56, 95% CI 2.36–2.78), or were treated at a low-volume center (OR 2.10, 95% CI 1.63–2.71). Among patients receiving upfront chemotherapy, only 33.5% underwent subsequent resection. Resection was more likely in patients with T1 tumors (OR 1.22, 95% CI 1.04–1.43) and in those treated at high-volume centers (OR 4.03, 95% CI 2.90–5.60). Only 20.4% of hospitals performed resection in > 50% of patients after upfront chemotherapy. Conclusion: Rates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.

Original languageEnglish (US)
JournalAnnals of surgical oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pancreatic Neoplasms
Drug Therapy
Odds Ratio
Confidence Intervals
Neoplasms
Adenocarcinoma
Quality of Health Care
Logistic Models
Databases

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{236be5cecb22462599bf421c467454dd,
title = "National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection",
abstract = "Introduction: Chemotherapy is increasingly administered prior to resection in patients with early-stage pancreatic adenocarcinoma, but the national prevalence of this practice is poorly understood. Our objectives were to (1) describe the utilization of upfront chemotherapy management of stage I pancreatic cancer; (2) define factors associated with the use of upfront chemotherapy and subsequent resection; and (3) assess hospital-level variability in upfront chemotherapy and subsequent resection. Methods: The National Cancer Database was used to identify patients treated for clinical stage I pancreatic adenocarcinoma. Outcomes were receipt of upfront chemotherapy and surgical resection after upfront chemotherapy. Associations between patient/hospital factors and both initial management and subsequent resection were assessed by multivariable logistic regression. Results: A total of 17,495 patients were included, with 26.6{\%} receiving upfront chemotherapy. Upfront chemotherapy was more likely in patients who were ≥ 80 years of age (odds ratio [OR] 1.64, 95{\%} confidence interval [CI] 1.39–1.93), had T2 tumors (OR 2.56, 95{\%} CI 2.36–2.78), or were treated at a low-volume center (OR 2.10, 95{\%} CI 1.63–2.71). Among patients receiving upfront chemotherapy, only 33.5{\%} underwent subsequent resection. Resection was more likely in patients with T1 tumors (OR 1.22, 95{\%} CI 1.04–1.43) and in those treated at high-volume centers (OR 4.03, 95{\%} CI 2.90–5.60). Only 20.4{\%} of hospitals performed resection in > 50{\%} of patients after upfront chemotherapy. Conclusion: Rates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.",
author = "Ellis, {Ryan J.} and Ho, {Jessie W.} and Schlick, {Cary Jo R.} and Merkow, {Ryan P.} and Bentrem, {David J.} and Bilimoria, {Karl Y.} and Yang, {Anthony D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1245/s10434-019-08023-1",
language = "English (US)",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection

AU - Ellis, Ryan J.

AU - Ho, Jessie W.

AU - Schlick, Cary Jo R.

AU - Merkow, Ryan P.

AU - Bentrem, David J.

AU - Bilimoria, Karl Y.

AU - Yang, Anthony D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Chemotherapy is increasingly administered prior to resection in patients with early-stage pancreatic adenocarcinoma, but the national prevalence of this practice is poorly understood. Our objectives were to (1) describe the utilization of upfront chemotherapy management of stage I pancreatic cancer; (2) define factors associated with the use of upfront chemotherapy and subsequent resection; and (3) assess hospital-level variability in upfront chemotherapy and subsequent resection. Methods: The National Cancer Database was used to identify patients treated for clinical stage I pancreatic adenocarcinoma. Outcomes were receipt of upfront chemotherapy and surgical resection after upfront chemotherapy. Associations between patient/hospital factors and both initial management and subsequent resection were assessed by multivariable logistic regression. Results: A total of 17,495 patients were included, with 26.6% receiving upfront chemotherapy. Upfront chemotherapy was more likely in patients who were ≥ 80 years of age (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.39–1.93), had T2 tumors (OR 2.56, 95% CI 2.36–2.78), or were treated at a low-volume center (OR 2.10, 95% CI 1.63–2.71). Among patients receiving upfront chemotherapy, only 33.5% underwent subsequent resection. Resection was more likely in patients with T1 tumors (OR 1.22, 95% CI 1.04–1.43) and in those treated at high-volume centers (OR 4.03, 95% CI 2.90–5.60). Only 20.4% of hospitals performed resection in > 50% of patients after upfront chemotherapy. Conclusion: Rates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.

AB - Introduction: Chemotherapy is increasingly administered prior to resection in patients with early-stage pancreatic adenocarcinoma, but the national prevalence of this practice is poorly understood. Our objectives were to (1) describe the utilization of upfront chemotherapy management of stage I pancreatic cancer; (2) define factors associated with the use of upfront chemotherapy and subsequent resection; and (3) assess hospital-level variability in upfront chemotherapy and subsequent resection. Methods: The National Cancer Database was used to identify patients treated for clinical stage I pancreatic adenocarcinoma. Outcomes were receipt of upfront chemotherapy and surgical resection after upfront chemotherapy. Associations between patient/hospital factors and both initial management and subsequent resection were assessed by multivariable logistic regression. Results: A total of 17,495 patients were included, with 26.6% receiving upfront chemotherapy. Upfront chemotherapy was more likely in patients who were ≥ 80 years of age (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.39–1.93), had T2 tumors (OR 2.56, 95% CI 2.36–2.78), or were treated at a low-volume center (OR 2.10, 95% CI 1.63–2.71). Among patients receiving upfront chemotherapy, only 33.5% underwent subsequent resection. Resection was more likely in patients with T1 tumors (OR 1.22, 95% CI 1.04–1.43) and in those treated at high-volume centers (OR 4.03, 95% CI 2.90–5.60). Only 20.4% of hospitals performed resection in > 50% of patients after upfront chemotherapy. Conclusion: Rates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.

UR - http://www.scopus.com/inward/record.url?scp=85074782619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074782619&partnerID=8YFLogxK

U2 - 10.1245/s10434-019-08023-1

DO - 10.1245/s10434-019-08023-1

M3 - Article

C2 - 31691112

AN - SCOPUS:85074782619

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -